Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

23.1%

6 terminated/withdrawn out of 26 trials

Success Rate

76.0%

-10.5% vs industry average

Late-Stage Pipeline

27%

7 trials in Phase 3/4

Results Transparency

58%

11 of 19 completed trials have results

Key Signals

11 with results6 terminated

Enrollment Performance

Analytics

Phase 2
14(53.8%)
Phase 3
6(23.1%)
Phase 1
5(19.2%)
Phase 4
1(3.8%)
26Total
Phase 2(14)
Phase 3(6)
Phase 1(5)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT04618744Phase 2Completed

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

Role: collaborator

NCT04375436Phase 1Completed

Safety and Tolerability of NTRX-07 in Healthy Volunteers

Role: collaborator

NCT04606576Phase 3Terminated

Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Role: collaborator

NCT04754334Phase 3Terminated

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Role: collaborator

NCT05247528Phase 1Completed

Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects

Role: collaborator

NCT03290248Phase 1Completed

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Role: collaborator

NCT03467932Phase 2Completed

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT04150107Phase 2Completed

A Study to Compare ORMD-0801 Once Daily to ORMD-0801 Three Times Daily in Subjects With Type 1 Diabetes

Role: collaborator

NCT00817414Phase 2Completed

A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With Hypertension

Role: collaborator

NCT00817635Phase 2Completed

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Role: collaborator

NCT02496000Phase 2Completed

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Role: collaborator

NCT03819881Phase 1Unknown

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Role: collaborator

NCT00791258Phase 4Completed

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

Role: collaborator

NCT03156361Phase 2Completed

21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus

Role: collaborator

NCT02794155Phase 2Completed

Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)

Role: collaborator

NCT03096392Phase 2Completed

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

Role: collaborator

NCT02954601Phase 2Completed

A Study of Single and Multiple Doses of Oral Insulin or Placebo in Subjects With Type 2 Diabetes Mellitus

Role: collaborator

NCT00459745Phase 3Completed

A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia

Role: collaborator

NCT02537470Phase 2Completed

Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes

Role: collaborator

NCT01840085Phase 3Terminated

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

Role: collaborator